All In Biotech

Drug Trial Radar · NCT06206733

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

A Phase III Study Evaluating the Efficacy and Safety of ASKB589 Combined With CAPOX and PD-1 Inhibitor as First-Line Treatment in Claudin18.2 Positive Patients With Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 780 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

780

Planned (sponsor's estimate)

Start

Jan 25, 2024

Primary completion

Dec 30, 2026

Study completion Dec 30, 2028

Sponsor

Lead sponsor
AskGene Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Jiangsu Aosaikang Pharmaceutical Co., Ltd.; Jiangsu Aosaikang Biopharmaceutical Co., Ltd
First posted
Jan 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, standard-of-care controlled phase III clinical study conducted in China. The purpose of this study is to evaluate the efficacy of ASKB589 plus CAPOX and PD-1 inhibitor compared with placebo plus CAPOX and PD-1 inhibitor (as first-line treatment) as measured by Progression Free Survival (PFS).

Conditions

  • Gastroesophageal Junction Adenocarcinoma
  • Gastric Adenocarcinoma

Interventions

  • ASKB589Drug

    ASKB589 will be administered as a minimum 3-hour IV infusion

  • OxaliplatinDrug

    Oxaliplatin will be administered as a minimum 2-hour IV infusion

  • CapecitabineDrug

    Capecitabine will be administered orally twice daily (bid).

  • TislelizumabDrug

    Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.

  • PlaceboDrug

    Placebo will be administered as a minimum 3-hour IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Until disease progression or withdrawal from the study (generally up to 24 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing cancer hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.